Abstract 195P
Background
Cervical cancer (CC) is one of the most preventable cancers among women due to the existence of human papillomavirus (HPV) vaccine. HPV vaccines reduce cervical cancer risk and protect against other HPV-associated cancers.
Methods
This a survey-based cross-sectional study that aims to evaluate the level of knowledge about HPV infection, CC and vaccine among Omani females. The survey was constructed from the NCI-HINTS survey after permission. The Arabic version of the survey was piloted and validated with good reliability score. The survey was distributed as a link in different social media platforms between August 2020- December 2020. There were 468 female participants from different regions of the Sultanate of Oman.
Results
Approximately 45% of the participants were 30-39 years old. The majority of participants (65.9%) were not aware about the need for Pap smear every three years as a screening for CC. Most of the participating females (88.4%) were willing to have Pap smears every three years if their health care provider recommended it. Few participants (22%) had heard about HPV. Most of the participants have never been examined or are aware if they have HPV infection. Almost all participants (93.8%) believe that HPV infection necessitates medical treatment. About a third (38.7%) are aware that HPV infection can cause cervical cancer and 60% females know that HPV can cause abnormal Pap smears. The vast majority (87%) of the participants have not heard of HPV vaccine as a preventive measure from CC. This study showed a significant association between age and the level of knowledge about the recent changes in the guidelines related to CC screening (p<0.05). It also demonstrates that there is no correlation between accepting to give their daughter the vaccine and their awareness of CC. Additionally, there was no significant association between age and their acceptance of doing Pap smear or their knowledge about HPV vaccine, but there is a significant correlation between age and the willingness to give the vaccine to their daughters (p<0.05).
Conclusions
Among Omani females of different age groups, there is a lack of knowledge regarding CC. In these contexts, efforts to promote HPV vaccination for cancer prevention remain critical.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03